WO2010109706A1 - 分子標的薬に対する感受性が低下している癌の治療薬および分子標的薬に対する感受性を増強する医薬組成物 - Google Patents
分子標的薬に対する感受性が低下している癌の治療薬および分子標的薬に対する感受性を増強する医薬組成物 Download PDFInfo
- Publication number
- WO2010109706A1 WO2010109706A1 PCT/JP2009/067630 JP2009067630W WO2010109706A1 WO 2010109706 A1 WO2010109706 A1 WO 2010109706A1 JP 2009067630 W JP2009067630 W JP 2009067630W WO 2010109706 A1 WO2010109706 A1 WO 2010109706A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- hgf
- met receptor
- inhibitor
- pharmaceutical composition
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 103
- 229940079593 drug Drugs 0.000 title claims abstract description 100
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 97
- 201000011510 cancer Diseases 0.000 title claims abstract description 68
- 230000035945 sensitivity Effects 0.000 title claims abstract description 56
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 28
- 229940124597 therapeutic agent Drugs 0.000 title claims abstract description 20
- 230000002829 reductive effect Effects 0.000 title claims description 28
- 230000002708 enhancing effect Effects 0.000 title description 2
- 239000003112 inhibitor Substances 0.000 claims abstract description 33
- 239000012830 cancer therapeutic Substances 0.000 claims abstract description 23
- 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims description 130
- 102100021866 Hepatocyte growth factor Human genes 0.000 claims description 123
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims description 123
- 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 claims description 123
- 108020003175 receptors Proteins 0.000 claims description 94
- 102000005962 receptors Human genes 0.000 claims description 80
- 230000003472 neutralizing effect Effects 0.000 claims description 48
- 108090000623 proteins and genes Proteins 0.000 claims description 41
- 229940121647 egfr inhibitor Drugs 0.000 claims description 32
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 29
- 201000005202 lung cancer Diseases 0.000 claims description 29
- 208000020816 lung neoplasm Diseases 0.000 claims description 29
- 102000004169 proteins and genes Human genes 0.000 claims description 22
- 230000014509 gene expression Effects 0.000 claims description 12
- 230000003247 decreasing effect Effects 0.000 claims description 11
- 230000002427 irreversible effect Effects 0.000 claims description 10
- 229940126585 therapeutic drug Drugs 0.000 claims description 9
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 claims description 7
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 claims description 7
- 229940124617 receptor tyrosine kinase inhibitor Drugs 0.000 claims description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 6
- 230000003321 amplification Effects 0.000 claims description 6
- 206010017758 gastric cancer Diseases 0.000 claims description 6
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 6
- 230000002441 reversible effect Effects 0.000 claims description 6
- 201000011549 stomach cancer Diseases 0.000 claims description 6
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 5
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 5
- 206010009944 Colon cancer Diseases 0.000 claims description 5
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 5
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 5
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 5
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 208000029742 colonic neoplasm Diseases 0.000 claims description 5
- 201000004101 esophageal cancer Diseases 0.000 claims description 5
- 201000010175 gallbladder cancer Diseases 0.000 claims description 5
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 5
- 201000010982 kidney cancer Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 abstract description 99
- 229960002584 gefitinib Drugs 0.000 abstract description 99
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 abstract description 99
- 239000005551 L01XE03 - Erlotinib Substances 0.000 abstract description 10
- 229960001433 erlotinib Drugs 0.000 abstract description 10
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 abstract description 10
- 210000004027 cell Anatomy 0.000 description 70
- 101000998139 Homo sapiens Interleukin-32 Proteins 0.000 description 45
- 238000000034 method Methods 0.000 description 25
- 230000000694 effects Effects 0.000 description 22
- 102000001301 EGF receptor Human genes 0.000 description 21
- 108060006698 EGF receptor Proteins 0.000 description 21
- 230000035772 mutation Effects 0.000 description 20
- 239000004055 small Interfering RNA Substances 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 15
- 239000002609 medium Substances 0.000 description 15
- 230000035755 proliferation Effects 0.000 description 14
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 13
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 13
- 238000012258 culturing Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 108020004459 Small interfering RNA Proteins 0.000 description 10
- 230000012010 growth Effects 0.000 description 10
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 108091027967 Small hairpin RNA Proteins 0.000 description 9
- -1 antibodies Proteins 0.000 description 9
- 230000019491 signal transduction Effects 0.000 description 9
- 230000004544 DNA amplification Effects 0.000 description 8
- 239000013604 expression vector Substances 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 238000011579 SCID mouse model Methods 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 102000057308 human HGF Human genes 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 230000007423 decrease Effects 0.000 description 6
- 210000002950 fibroblast Anatomy 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 5
- 229930182555 Penicillin Natural products 0.000 description 5
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 5
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 229940049954 penicillin Drugs 0.000 description 5
- 235000002639 sodium chloride Nutrition 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- 239000013603 viral vector Substances 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 239000000074 antisense oligonucleotide Substances 0.000 description 4
- 238000012230 antisense oligonucleotides Methods 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 4
- 229920000053 polysorbate 80 Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000005215 recombination Methods 0.000 description 4
- 230000006798 recombination Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010071975 EGFR gene mutation Diseases 0.000 description 3
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 3
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 101800004564 Transforming growth factor alpha Proteins 0.000 description 3
- 102400001320 Transforming growth factor alpha Human genes 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229960005395 cetuximab Drugs 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 102000046616 human IL32 Human genes 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 2
- 235000005956 Cosmos caudatus Nutrition 0.000 description 2
- 230000006820 DNA synthesis Effects 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229950008138 carmellose Drugs 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000001727 glucose Nutrition 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 108091006082 receptor inhibitors Proteins 0.000 description 2
- 229940083542 sodium Drugs 0.000 description 2
- 235000015424 sodium Nutrition 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- 229960003787 sorafenib Drugs 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 241000702421 Dependoparvovirus Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 101150039808 Egfr gene Proteins 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 101150022655 HGF gene Proteins 0.000 description 1
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- UCEQXRCJXIVODC-PMACEKPBSA-N LSM-1131 Chemical compound C1CCC2=CC=CC3=C2N1C=C3[C@@H]1C(=O)NC(=O)[C@H]1C1=CNC2=CC=CC=C12 UCEQXRCJXIVODC-PMACEKPBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 101150105382 MET gene Proteins 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 241000711408 Murine respirovirus Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- OYONTEXKYJZFHA-SSHUPFPWSA-N PHA-665752 Chemical compound CC=1C(C(=O)N2[C@H](CCC2)CN2CCCC2)=C(C)NC=1\C=C(C1=C2)/C(=O)NC1=CC=C2S(=O)(=O)CC1=C(Cl)C=CC=C1Cl OYONTEXKYJZFHA-SSHUPFPWSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- BCZUAADEACICHN-UHFFFAOYSA-N SGX-523 Chemical compound C1=NN(C)C=C1C1=NN2C(SC=3C=C4C=CC=NC4=CC=3)=NN=C2C=C1 BCZUAADEACICHN-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229960004543 anhydrous citric acid Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229950002826 canertinib Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 108700021358 erbB-1 Genes Proteins 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 102000057421 human MET Human genes 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229960001001 ibritumomab tiuxetan Drugs 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- LDHBWEYLDHLIBQ-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide;hydrate Chemical compound O.[OH-].[O-2].[Fe+3] LDHBWEYLDHLIBQ-UHFFFAOYSA-M 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 108010066733 mRNA (guanine(N7))-methyltransferase Proteins 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- WVUNYSQLFKLYNI-AATRIKPKSA-N pelitinib Chemical compound C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC1=CC=C(F)C(Cl)=C1 WVUNYSQLFKLYNI-AATRIKPKSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 210000003370 receptor cell Anatomy 0.000 description 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960000999 sodium citrate dihydrate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 229950010130 tamibarotene Drugs 0.000 description 1
- MUTNCGKQJGXKEM-UHFFFAOYSA-N tamibarotene Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1NC(=O)C1=CC=C(C(O)=O)C=C1 MUTNCGKQJGXKEM-UHFFFAOYSA-N 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 229950005976 tivantinib Drugs 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Definitions
- the present invention relates to a pharmaceutical composition for enhancing the sensitivity of a molecular target drug to a target cancer of a cancer that is a therapeutic target of the molecular target drug, but a cancer in which the molecular target drug is ineffective, or a cancer whose sensitivity to the molecular target drug is reduced, and It relates to therapeutic drugs.
- Lung cancer is the number one malignant tumor in Japan, and the establishment of an effective treatment is an urgent issue.
- epidermal growth factor receptor hereinafter referred to as “EGFR”
- EGFR epidermal growth factor receptor
- erlotinib epidermal growth factor receptor
- lung cancer cases with EGFR gene mutations and non- EGFR tyrosine kinase inhibitor is considered to be a specific drug for lung cancer because it is effective for smokers.
- Non-Patent Document 1 shows that MET gene amplification is observed in lung cancer cells that have acquired gefitinib resistance, and the combination of a MET inhibitor and gefitinib results in an increase in the gefitinib-resistant lung cancer cells. It is described that the growth was suppressed.
- the present inventors have reported that induction of gefitinib resistance to Skills gastric cancer cells by interaction with fibroblasts was suppressed by the combined use of NK4 gene therapy (see Non-Patent Document 2).
- the present invention is a pharmaceutical composition that enhances the sensitivity of a cancer that is resistant to a molecular target drug such as gefitinib or erlotinib, and a cancer that is resistant to a molecular target drug such as gefitinib or erlotinib. It aims at providing a cancer therapeutic agent.
- the present invention includes the following inventions in order to solve the above problems.
- a pharmaceutical composition that enhances the sensitivity of a molecular target drug to a target cancer of a cancer for which the molecular target drug is ineffective, or a cancer in which the molecular target drug is ineffective or has decreased sensitivity to the molecular target drug.
- a pharmaceutical composition comprising an inhibitor of the HGF-MET receptor system.
- the pharmaceutical composition according to [1] or [2], wherein the molecular target drug is an EGFR tyrosine kinase inhibitor.
- the EGFR inhibitor is an irreversible EGFR tyrosine kinase inhibitor.
- the HGF-MET receptor system inhibitor is an anti-HGF neutralizing antibody, NK4, MET receptor tyrosine kinase inhibitor, anti-MET receptor antibody, MET receptor expression inhibitor, and HGF in the MET receptor extracellular region
- Cancer targeted for treatment with molecular targeted drugs is lung cancer, breast cancer, colon cancer, prostate cancer, brain tumor, pancreatic cancer, gallbladder cancer, renal cancer, chronic myelogenous leukemia, gastrointestinal stromal tumor, esophageal cancer, head and neck
- a therapeutic drug for cancer that is a cancer to be treated with a molecular target drug, but the molecular target drug is ineffective or whose sensitivity to the molecular target drug is decreased, and the molecular target drug and HGF-MET A therapeutic drug for cancer, comprising a combination with a receptor system inhibitor.
- the HGF-MET receptor system inhibitor is an anti-HGF neutralizing antibody, NK4, a MET receptor tyrosine kinase inhibitor, an anti-MET receptor antibody, a MET receptor expression inhibitor, and an HGF in the MET receptor extracellular region.
- the cancer therapeutic drug according to any one of [8] to [12], which is at least one selected from the group consisting of proteins having a binding moiety.
- the target cancer of the molecular target drug is lung cancer, breast cancer, colon cancer, prostate cancer, brain tumor, pancreatic cancer, gallbladder cancer, renal cancer, chronic myelogenous leukemia, gastrointestinal stromal tumor, esophageal cancer, head and neck
- the cancer therapeutic agent according to any one of [8] to [13], which is a tumor or gastric cancer.
- the present invention it is possible to provide a pharmaceutical composition that enhances the sensitivity of a cancer having resistance to a molecular target drug such as gefitinib or erlotinib to the molecular target drug.
- a pharmaceutical composition that enhances the sensitivity of a cancer having resistance to a molecular target drug such as gefitinib or erlotinib to the molecular target drug.
- an effective cancer therapeutic drug for cancer that exhibits resistance to molecular target drugs such as gefitinib and erlotinib.
- the present invention brings the gospel to cancer patients, and its social significance is extremely great.
- FIG. 3 shows the proliferation rate of PC-9 lung cancer cells after 72 hours of culture with or without addition. It is a figure which shows the result of having examined the combined use effect of the anti- HGF neutralizing antibody or NK4, and gefitinib with respect to the tumor derived from the gefitinib sensitivity human lung cancer cell transplanted to the back of SCID mouse
- the pharmaceutical composition of the present invention contains a HGF-MET receptor system inhibitor and is a cancer targeted for treatment by a molecular target drug, but the molecular target drug is ineffective or sensitivity to the molecular target drug is reduced This enhances the sensitivity of cancer to the molecular target drug.
- the cancer therapeutic agent of the present invention comprises a combination of a molecular target drug and an HGF-MET receptor system inhibitor, and is a cancer to be treated by the molecular target drug, but the molecular target drug is ineffective or the molecule
- the target of treatment is cancer with reduced sensitivity to the target drug.
- Molecular targeting drugs are drugs that are designed to capture specific properties of cancer cells at the molecular level and act efficiently by targeting them. Proteins such as antibodies, peptides, nucleic acids, low molecular compounds, etc. Is included.
- the molecular target drug in the present invention is not limited, and for example, gefitinib, erlotinib, imatinib, ibritumomab tiuxetan, gemtuzumab ozogamicin, sunitinib, cetuximab, sorafenib, tamibarotene, trastuzumab, tretinoin, panitumumab, bebatizumab, , Known molecular targeting drugs such as rituximab, vandetanib, lapatinib, sorafenib, cetuximab and the like.
- an EGFR (Epidermal Growth Factor Receptor) tyrosine kinase inhibitor is preferred.
- An EGFR tyrosine kinase inhibitor is a drug that exerts an anticancer effect by inhibiting signal transduction from EGFR expressed on the surface of cancer cells.
- the EGFR tyrosine kinase inhibitor includes a reversible EGFR tyrosine kinase inhibitor and an irreversible EGFR tyrosine kinase inhibitor, and any EGFR tyrosine kinase inhibitor is suitable as a molecular target drug in the present invention.
- reversible EGFR tyrosine kinase (including EGFR family) inhibitors include gefitinib, erlotinib, cetuximab, trastuzumab and the like
- irreversible EGFR tyrosine kinase inhibitors include, for example, EKB569, HKI2721, BIBW2992, PF299804, CL-387, 785, CI-1033 and the like.
- the cancer to be treated by the molecular target drug is not limited, but for example, lung cancer, breast cancer, colon cancer, prostate cancer, brain tumor (glioma, glioblastoma, medulloblastoma, etc.), pancreatic cancer, gallbladder cancer, kidney Cancer, chronic myelogenous leukemia, gastrointestinal stromal tumor, esophageal cancer, head and neck tumor, gastric cancer and the like are preferable.
- Cancer with invalid molecular targeting drug is a mutation related to the molecule targeted by the molecular targeting drug, a mutation of other molecules that work in the signal transduction system related to the molecule, and a signal transmission system related to the molecule Cancers in which molecular targeted drugs are ineffective even though they are not directly related, due to mutations occurring in other molecules, overexpression, or activation caused by other causes.
- Such cancers include cancers that have such properties (drug resistance) before treatment with molecular targeted drugs, and cancers that have such properties as acquired during treatment with molecular targeted drugs. .
- cancer with reduced sensitivity to a molecular target drug is a mutation related to the molecule itself targeted by the molecular target drug, a mutation of another molecule that works in the signal transduction system related to the molecule, or a relationship of the molecule. Even though it is not directly related to the signal transduction system, it is a cancer whose sensitivity to a molecular target drug has decreased due to mutations occurring in other molecules, overexpression, or activation caused by other causes.
- Such cancers include cancers that have such properties (low sensitivity) before treatment with molecular targeted drugs and cancers that have such properties as acquired during treatment with molecular targeted drugs. It is.
- the cancer to be treated is non-small cell lung cancer, and in particular, EGFR having a mutation caused by deletion of exon 19 of the EGFR gene or an active mutation caused by mutation of Leu at position 858 to Thr. It is effective for non-small cell lung cancer that expresses.
- EGFR having a mutation caused by deletion of exon 19 of the EGFR gene or an active mutation caused by mutation of Leu at position 858 to Thr.
- a new mutation that occurs in EGFR such as mutation of Thr at 790th to Met
- gene amplification of the MET receptor invalidates gefitinib, or sensitivity to gefitinib Is known to decrease.
- MET receptor gene amplification was observed in about 20% of non-small cell lung cancers with EGFR-activated mutations with reduced sensitivity to gefitinib (see Non-Patent Document 1), and about 50% of EGFR A new mutation (such as T790M) is observed in the amino acid sequence.
- the present inventors have found that in non-small cell lung cancer having an EGFR active mutation, gefitinib is inactivated by the action of HGF, or the sensitivity to gefitinib is reduced. This finding indicates that activation of the HGF-MET receptor system is one of the causes of ineffectiveness or reduced sensitivity to molecular targeted drugs. As described above, MET receptor gene amplification was observed in about 20% of non-small cell lung cancers having an EGFR active mutation that became acquired resistance to gefitinib, and a new mutation was observed in EGFR in about 50%. However, the cause of the remaining 30% has not yet been elucidated.
- a cancer that is a target of treatment of a molecular target drug but the molecular target drug is ineffective or a cancer whose sensitivity to the molecular target drug is reduced is not particularly limited, but MET A cancer that does not involve amplification of a receptor gene is preferred. Whether the MET receptor gene is amplified is determined by, for example, extracting genomic DNA from the target cancer cell, performing quantitative PCR using an appropriate primer capable of amplifying the MET receptor gene portion, This can be confirmed by comparing the results with a sample of cells without body gene amplification.
- a cancer targeted for treatment with a molecular target drug but a cancer in which the molecular target drug is ineffective or sensitivity to the molecular target drug is reduced refers to activation of the HGF-MET receptor system. It is preferable that the cancer is ineffective or reduced in sensitivity. Particularly preferred is a cancer that is not accompanied by amplification of the MET receptor gene and in which ineffectiveness or reduced sensitivity is induced by activation of the HGF-MET receptor system.
- the HGF-MET receptor system inhibitor means a substance that inhibits signal transduction from the MET receptor, and includes proteins, peptides, nucleic acids, low molecular compounds, and the like. Specifically, it acts on HGF to inhibit the binding between HGF and the MET receptor, acts on the MET receptor to inhibit the binding between HGF and the MET receptor, acts on the MET receptor and acts on the MET receptor. Signal transduction from the MET receptor is inhibited by inhibiting signal transduction from the body, inhibiting expression of the MET receptor, and the like.
- Suitable HGF-MET receptor inhibitor in the present invention includes, for example, anti-HGF neutralizing antibody, NK4, MET receptor tyrosine kinase inhibitor, anti-MET receptor antibody, MET receptor expression inhibitor, MET receptor cell Examples include proteins having an HGF-binding portion in the outer region.
- the anti-HGF neutralizing antibody may be an antibody that binds to HGF and reduces or eliminates its activity. Examples thereof include an anti-HGF antibody that binds to HGF and prevents HGF from binding to the MET receptor.
- the anti-HGF neutralizing antibody can be prepared by a known method described later using HGF or a fragment thereof as an immunogen. Whether the obtained antibody is a neutralizing antibody can be confirmed by examining that the activity of HGF is neutralized by the obtained antibody. Specifically, for example, it was confirmed by examining the activity of neutralizing the DNA synthesis promoting action of primary cultured hepatocytes by HGF, or the activity of neutralizing the cell dispersion promoting action of MDCK canine renal epithelial cells caused by HGF. can do.
- the HGF-MET receptor system inhibitors in the present invention include humanized monoclonal antibodies against HGF that are already being developed or will be developed in the future.
- NK4 is a protein having an N-terminal hairpin domain of the ⁇ chain of HGF and four kringle domains, and binds to the MET receptor and acts as an antagonist of HGF (Date.K et al., FEBS Lett, 420, 1). -6 (1997), Date. K et al., Oncogene, 17, 3045-3054 (1998)).
- NK4 can be obtained by, for example, constructing an NK4 expression vector by a known gene recombination technique using a gene encoding NK4, introducing the NK4 expression vector into an appropriate host, and recovering and purifying the recombinant NK4. it can.
- a gene drug or gene therapy vector by incorporating a gene encoding NK4 into an appropriate vector and using the NK4 expression vector is also included in NK4 as an inhibitor of the HGF-MET receptor system.
- Examples of the gene encoding NK4 include, but are not limited to, a gene consisting of the base sequence shown in SEQ ID NO: 1 or 3.
- the protein encoded by the NK4 gene consisting of the base sequence of SEQ ID NO: 1 is NK4 consisting of the amino acid sequence of SEQ ID NO: 2
- the protein encoded by the NK4 gene consisting of the base sequence of SEQ ID NO: 3 is the amino acid sequence of SEQ ID NO: 4.
- the MET receptor tyrosine kinase inhibitor may be any substance that suppresses the tyrosine kinase activity of the MET receptor.
- SU11274 Pfizer
- PHA665752 Pfizer
- PF23441066 Pfizer
- XL880 Exelixis
- ARQ197 ARQ197
- MK2461 Merck
- MP470 SuperGen
- SGX523 SGX Pharmaceutical
- JNJ38887705 Johnson & Johnson
- MET receptor Also included are molecules that inhibit tyrosine kinase activity.
- the anti-MET receptor antibody may be an antibody that binds to the MET receptor and inhibits signal transduction.
- an antibody that binds to the HGF binding site of the MET receptor and inhibits the binding of HGF can be mentioned.
- the anti-MET receptor antibody can be prepared by a known method described later using the MET receptor or a fragment thereof as an immunogen. Whether the obtained antibody is an antibody that inhibits signal transduction can be confirmed, for example, by examining that the activity of HGF is neutralized by the obtained antibody.
- the MET receptor expression inhibitor may be any substance that suppresses the expression of the MET receptor.
- Examples thereof include MET receptor gene siRNA (short interfering RNA), shRNA (short hairpin RNA), and antisense oligonucleotide. It is done.
- Examples of the MET receptor gene include, but are not limited to, a gene having a base sequence represented by SEQ ID NO: 5.
- An siRNA is a double-stranded RNA having a length of about 20 bases (for example, about 21 to 23 bases) or less, and by expressing such siRNA in a cell, a gene (this In the invention, the expression of the MET receptor gene) can be suppressed.
- shRNA is a single-stranded RNA that contains a partially palindromic base sequence, so that it has a double-stranded structure in the molecule and a short hairpin structure having a protruding portion at the 3 ′ end. It refers to the above molecules.
- shRNA is introduced into the cell, it is degraded into a length of about 20 bases (typically, for example, 21 bases, 22 bases, 23 bases) in the cell and becomes a target in the same manner as siRNA.
- Expression of a gene (MET receptor gene in the present invention) can be suppressed.
- the siRNA and shRNA may be in any form as long as the expression of the MET receptor gene can be suppressed.
- siRNA or shRNA can be artificially chemically synthesized.
- antisense and sense RNA can be synthesized in vitro from template DNA using T7 RNA polymerase and T7 promoter.
- the antisense oligonucleotide may be any nucleotide that is complementary to or hybridizes to a continuous 5 to 100 nucleotide sequence in the DNA sequence of the MET receptor gene, and may be either DNA or RNA. . Moreover, it may be modified as long as the function is not hindered.
- Antisense oligonucleotides can be synthesized by a conventional method, and can be easily synthesized, for example, by a commercially available DNA synthesizer (for example, manufactured by Applied Biosystems).
- the protein having the HGF binding portion of the MET receptor extracellular region may be any protein that has an HGF binding portion of the MET receptor extracellular region and binds to HGF.
- examples thereof include a protein having a HGF binding portion that is a partial protein of the MET receptor extracellular region, a protein having a HGF binding portion of the MET receptor extracellular region, and a protein other than the MET receptor extracellular region.
- an expression vector is constructed by a known gene recombination technique using a part of the gene encoding the MET receptor, and this is introduced into an appropriate host. The recombinant protein expressed in this manner can be recovered and purified.
- the extracellular region of the MET receptor corresponds to positions 1 to 932 of the amino acid sequence (see SEQ ID NO: 6, GenBank Accession No. X54559) (reference: Michieli P, Mazzone M, BasilicosilC, Cavassa S, Sottile A, Naldini L, Comoglio PM. Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. Cancer Cell. 2004) 6: 61-73.
- the HGF-MET receptor system inhibitor is an antibody (for example, an anti-HGF neutralizing antibody, an anti-MET receptor antibody, etc.), it may be a polyclonal antibody or a monoclonal antibody. Further, it may be a complete antibody molecule or an antibody fragment that can specifically bind to an antigen (for example, Fab fragment, F (ab ′) 2 fragment, etc.).
- a polyclonal antibody can be prepared and obtained, for example, as follows.
- an antigen for example, HGF, a MET receptor or a fragment thereof
- a mammal for example, a method of subcutaneous injection or intraperitoneal injection once or a plurality of times at an appropriate interval is preferable.
- blood can be collected from the immunized animal, serum can be separated, and the polyclonal antibody fraction can be purified.
- Monoclonal antibodies can be obtained by fusing immune cells (eg, spleen cells) obtained from the immunized mammal and myeloma cells to obtain a hybridoma, and collecting the antibody from the hybridoma culture to obtain the monoclonal antibody. it can.
- an antibody gene can be cloned from a hybridoma, incorporated into an appropriate vector, introduced into a host, and a recombinant monoclonal antibody can be produced using gene recombination techniques.
- a chimeric antibody modified so as to have the same constant region as that of a human antibody, or a humanized antibody derived from a region other than CDR (complementarity determining region) is used. It is preferable to use a human monoclonal antibody produced using a transgenic animal such as a mouse into which a human gene involved in antibody production is introduced. Moreover, the phage display method can also be used for human-type antibody production.
- the antigen recognition region of the antibody thus obtained can be excised with a protease or the like and used as Fv, Fab or F (ab ′) 2 .
- a human-derived protein can be produced as a recombinant protein by a known gene recombination technique using a human gene encoding the protein.
- the base sequence of human NK4 gene is shown in SEQ ID NO: 1 or 3, and the amino acid sequence encoded by these is shown in SEQ ID NO: 2 or 4, respectively.
- the base sequence of the human MET receptor gene is shown in SEQ ID NO: 5, and the encoded amino acid sequence is shown in SEQ ID NO: 6.
- the pharmaceutical composition of the present invention may be formulated by appropriately blending carriers or additives that are usually used in the pharmaceutical field, with an HGF-MET receptor system inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient. it can.
- oral preparations such as tablets, coated tablets, pills, powders, granules, capsules, solutions, suspensions and emulsions; parenterals such as injections, suppositories, ointments and patches Can do. What is necessary is just to set suitably about the mixture ratio of a carrier or an additive based on the range normally employ
- Carriers or additives that can be blended are not particularly limited.
- water, saline, other aqueous solvents for example, water, saline, other aqueous solvents; various carriers such as aqueous or oily bases; excipients, binders, pH adjusters, disintegrants, absorption
- Various additives such as an accelerator, a lubricant, a colorant, a corrigent, and a fragrance are included.
- additives include lactose, sucrose, mannitol, sodium chloride, glucose, calcium carbonate, kaolin, crystalline cellulose, silicate and other excipients; water, ethanol, simple syrup, glucose solution, Binding agents such as starch solution, gelatin solution, carboxymethylcellulose, carboxymethylcellulose Na, shellac, methylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, polyvinylpyrrolidone, polyvinyl alcohol, gelatin, dextrin, pullulan; citric acid, anhydrous citric acid, citric acid PH adjusters such as sodium, sodium citrate dihydrate, anhydrous sodium monohydrogen phosphate, anhydrous sodium dihydrogen phosphate, sodium hydrogen phosphate, sodium dihydrogen phosphate; carmellose calcium Disintegrating agents such as low-substituted hydroxypropycellulose, carmellose, croscarmellose sodium, carboxymethyl starch sodium, crospovidone, polysorbate 80; other absorption
- the active ingredient of the pharmaceutical composition of the present invention is a nucleic acid (siRNA, shRNA, antisense oligonucleotide, etc.)
- it can be administered in the form of a non-viral vector or a viral vector.
- a non-viral vector form a method for introducing nucleic acid molecules using liposomes (liposome method, HVJ-liposome method, cationic liposome method, lipofection method, lipofectamine method, etc.), microinjection method, gene gun (Gene Gun ), A method of transferring a nucleic acid molecule into a cell together with a carrier (metal particle) can be used.
- a viral vector such as a recombinant adenovirus or a retrovirus
- DNA expressing siRNA or shRNA is added to DNA viruses or RNA viruses such as detoxified retrovirus, adenovirus, adeno-associated virus, herpes virus, vaccinia virus, pox virus, poliovirus, Sindbis virus, Sendai virus, SV40, etc.
- a gene can be introduced into a cell or tissue by introducing and infecting the cell or tissue with this recombinant virus.
- the dosage of the pharmaceutical composition of the present invention is appropriately determined in consideration of the purpose, the severity of the disease, the patient's age, weight, sex, medical history, type of active ingredient, and the like.
- an average human having a body weight of about 65 to 70 kg is used as a target, about 0.05 mg to 2000 mg per day is preferable, and about 0.1 mg to 200 mg is more preferable.
- the total daily dose may be a single dose or divided doses.
- the cancer therapeutic agent of the present invention may be any combination of a molecular target drug and an HGF-MET receptor system inhibitor, for example, a combination of a molecular target drug and the above pharmaceutical composition of the present invention. Is preferred.
- the HGF-MET receptor system inhibitor may be administered simultaneously with the molecular targeted drug. Further, the molecular target drug may be administered sequentially after the administration of the HGF-MET receptor system inhibitor, or the HGF-MET receptor system inhibitor may be administered sequentially after the administration of the molecular target drug. . Furthermore, the HGF-MET receptor system inhibitor may be administered, and the molecular target drug may be administered separately at a certain time.
- the molecular target drug may be administered, and the HGF-MET receptor system inhibitor may be separately treated at a time. May be administered.
- the administration sequence and administration interval should be appropriately selected according to the preparation containing the HGF-MET receptor inhibitor, the molecular target drug used in combination with it, the type of cancer cell to be treated, the patient's condition, etc. Can do.
- “simultaneously” refers to administration at approximately the same time, and “separately” refers to administration separately at different times, for example, one drug on the first day, two days This refers to the case where another drug is administered to the eye.
- “Sequentially” refers to administration in order, for example, when one drug is administered first and then another drug is administered after a predetermined time.
- the cancer therapeutic agent of the present invention is a molecule that enhances the sensitivity of a cancer targeted for treatment with a molecular targeted drug, but for which the molecular targeted drug is ineffective or whose sensitivity to the molecular targeted drug is reduced. Since the target drug acts, it becomes possible to treat cancer very efficiently. In other words, even though treatment with molecular targeted drugs has been effective, sensitivity to molecular targeted drugs is often reduced by several factors, and an effect that can significantly reduce or almost completely eliminate cancer is observed. Absent. On the other hand, with the cancer therapeutic agent of the present invention, it is possible to bring about a therapeutic effect such that the cancer is remarkably reduced or almost completely eliminated.
- the cancer therapeutic agent of the present invention can bring about a therapeutic effect such that the cancer is remarkably reduced or almost completely disappeared, so that it is possible to significantly extend the life or to cure the cancer.
- the present invention brings the gospel to cancer patients, and its social significance is extremely great.
- the kit according to the present invention includes means such as a separate container, a separate bottle, and a separate foil packet for separately holding the molecular target drug and the preparation containing the HGF-MET receptor system inhibitor.
- the kit of the present invention is suitable for administering different compositions in different dosage forms at different dosage intervals.
- the kit includes instructions for administration, which may be written or printed on paper or other media, or electronic such as magnetic tape, computer readable disk or CD-ROM. It may be attached to the medium.
- Example 1 Induction of reduced gefitinib sensitivity by HGF to human non-small cell lung cancer cell lines expressing active mutant EGFR
- PC-9 human non-small cell lung cancer cell line
- HCC827 HCC827
- Both cells are cells in which neither a new mutation of EGFR involved in resistance to gefitinib (decrease in sensitivity) nor gene amplification of MET receptor is observed.
- PC-9 was purchased from the Institute for Immunobiology and HCC827 was purchased from ATCC.
- HGF recombinant human HGF protein
- penicillin 100 units / mL
- streptomycin 100 units / mL
- glutamine 2 mmol / L
- Gefitinib was obtained from AstraZeneca.
- HGF recombinant human HGF protein
- EGF and IGF-I were purchased from Invitrogen.
- TGF- ⁇ was purchased from Biosource.
- Anti-human HGF neutralizing antibody (goat) and control IgG (goat) were purchased from R & D System.
- MTT solution (2 mg / mL, Sigma) was added and incubated at 37 ° C. for 2 hours. The medium was removed and 100 ⁇ L of DMSO was added to each well to dissolve the dark blue crystals. Absorbance was measured at a detection wavelength of 550 nm and a reference wavelength of 630 nm using a microplate reader MTP-120 (Corona Electric). The growth rate is shown relative to the untreated control. Each experiment was performed in triplicate and three independent experiments were performed.
- the final concentrations in the medium were 20 ng / mL for HGF, 2 ⁇ g / mL for anti-human HGF neutralizing antibody, and 2 ⁇ g / mL for control IgG. After culturing for 72 hours, as in (a), cell proliferation was measured using the MTT method and the proliferation rate was calculated.
- HGF growth factors other than HGF
- EGF growth factors other than HGF
- TGF- ⁇ TGF- ⁇
- IGF-I growth factors other than HGF
- the induction ability is remarkable.
- HGF is against gefitinib, even in human non-small cell lung cancer cells that are sensitive to gefitinib and lack new mutations in EGFR and MET receptor gene amplification that are involved in resistance to gefitinib. It has been shown to reduce sensitivity, i.e. promote resistance to gefitinib.
- Example 2 Investigation using PC-9 introduced with HGF expression vector
- (1) Experimental material The same PC-9 as in Example 1 was used for the cells.
- HGF expression vector was prepared according to “Ueki T, Kaneda Y, Tsutsui H, et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nature Medicine 5, 226-230 (01 Feb 1999)”. The day before transfection, PC-9 prepared using a medium not containing antibiotics was seeded at 2 ⁇ 10 4 cells / 400 ⁇ L in a 24-well plate and cultured for 24 hours. The cells were transfected with an HGF expression vector using Lipofectamine 2000 (1 ⁇ L) (PC-9 / HGF). As a control, only the vector into which the HGF gene was not inserted was transfected in the same manner (PC-9 / mock).
- the cells were washed with PBS, and 0.3 ⁇ M (final concentration) gefitinib, 2 ⁇ g / ml (final concentration) anti-human HGF neutralizing antibody, 2 ⁇ g / ml (final concentration) control IgG, respectively. Incubation was continued for 72 hours with or without addition. After culturing for 72 hours, cell proliferation was measured using the MTT method in the same manner as in Example 1, and the proliferation rate was calculated.
- Example 3 Examination of effects of inhibitors of HGF-MET receptor system on gefitinib resistance of non-small cell lung cancer cells induced by fibroblast-derived HGF
- MRC-5 human embryonic lung-derived normal fibroblast MRC-5 (hereinafter referred to as “MRC-5”) were used as cells.
- MRC-5 is available from, for example, ATCC (ATCC No. CCL-171).
- RPMI1640 medium containing 10% FBS, penicillin (100 units / mL), streptomycin (100 units / mL), and glutamine (2 mmol / L) was used for the culture of PC-9, and 10% FBS was used for the culture of MRC-5.
- HGF recombinant human HGF protein
- NK4 recombinant human NK4 protein
- Anti-human HGF neutralizing antibody (goat) and control IgG (goat) for cultured cell experiments were purchased from R & D System.
- Anti-human HGF neutralizing antibody (immunoglobulin) for animal experiments was prepared by administering human HGF protein to rabbits, and purified from the antiserum by chromatography using a protein A column.
- Gefitinib was suspended in water containing 1% Tween 80 to a concentration of 2.5 mg / mL to prepare a suspension for administration.
- NK4 and anti-human HGF neutralizing antibody were prepared at concentrations of 1.13 mg / mL and 1.0 mg / mL using physiological saline (Otsuka Pharmaceutical Co., Ltd.), respectively, and used as solutions for administration.
- gefitinib administration group groups 4, 5 and 6 in Table 1
- gefitinib 25 mg / kg / day
- water containing 1% Tween 80 was orally administered once a day in the same manner.
- the anti-HGF neutralizing antibody administration groups (groups 2 and 5 in Table 1) were administered gefitinib once a day with anti-HGF neutralizing antibody (5 mg / kg / day) for 13 days from 4 to 16 days after cell inoculation. Immediately afterwards, intraperitoneal administration was performed.
- NK4 (9 mg / kg / day) was divided into twice a day for 13 days from 4 days to 16 days after cell inoculation, and in the morning and evening immediately after gefitinib administration Was administered intraperitoneally. The tumor width and length were measured every two days and the tumor area (width x length) was calculated. This experiment was conducted according to the guidelines of the British Cancer Research Coordinating Committee on Animal Welfare in Tumor Experiments.
- Example 4 Measurement of HGF concentration in xenograft tumor of SCID mice
- 100 ⁇ L of cell suspension containing PC-9 (5 ⁇ 10 6 ) and MRC-5 (5 ⁇ 10 6 ) was inoculated subcutaneously on the back of the SCID mouse, and the tumor was observed 4 days later. Were collected.
- As a control only PC-9 was inoculated in the same manner, and tumor tissue was collected 4 days later.
- the tumor tissue was homogenized in a protease inhibitor cocktail (20 mM Tris-HCl (pH 7.5), 2 M NaCl, 0.1% Tween-80, 2 mM EDTA, 1 mM PMSF), and then at 12,000 ⁇ g. Centrifuge for 30 minutes. The supernatant was used as an extract, and human HGF in the extract was quantified using an ELISA kit (IMMUNIS HGF EIA, Institute of Immunology).
- HGF was not detected from the tumor tissue formed by PC-9 alone, but high levels of HGF were detected from the tumor tissue formed by the mixed cells of PC-9 and MRC-5.
- HGF is produced by inoculating gefitinib-sensitive human non-small cell lung cancer cell line PC-9 with normal fibroblast MRC-5, and gefitinib resistance is induced in PC-9. It has been shown.
- H1975 human non-small cell lung cancer cell line H1975 (hereinafter referred to as “H1975”) resistant to gefitinib and sensitive to CL-387,785 was used.
- H1975 is available, for example, from ATCC (ATCC No. CRL-5908).
- RPMI1640 medium containing 10% FBS, penicillin (100 units / mL), streptomycin (100 units / mL), and glutamine (2 mmol / L) was used for the culture of H1975.
- Gefitinib was obtained from AstraZeneca.
- CL-387,785 was obtained from Cosmo Bio.
- HGF recombinant human HGF protein
- NK4 recombinant human NK4 protein
- Anti-human HGF neutralizing antibody (Lot No. ALP01) was purchased from R & D Systems.
- Absorbance was measured at a detection wavelength of 550 nm and a reference wavelength of 630 nm using a microplate reader MTP-120 (Corona Electric). The growth rate is shown relative to the untreated control. Each experiment was performed in triplicate and three independent experiments were performed.
- Example 6 Examination of effect of MET receptor tyrosine kinase inhibitor SU11274 on molecular target drug resistance of non-small cell lung cancer cells induced by HGF]
- PC-9 or H1975 was used for the cell.
- RPMI1640 medium containing 10% FBS, penicillin (100 units / mL), streptomycin (100 units / mL), and glutamine (2 mmol / L) was used.
- Gefitinib was obtained from AstraZeneca.
- CL-387,785 was obtained from Cosmo Bio.
- HGF recombinant human HGF protein
- NK4 recombinant human NK4 protein
- Anti-human HGF neutralizing antibody (goat) was purchased from R & D System.
- SU11274 was obtained from Calbiochem.
- the medium was removed and 100 ⁇ L of DMSO was added to each well to dissolve the dark blue crystals. Absorbance was measured at a detection wavelength of 550 nm and a reference wavelength of 630 nm using a microplate reader MTP-120 (Corona Electric). The growth rate is shown relative to the untreated control. Each experiment was performed in triplicate and three independent experiments were performed.
- FIG. 11 shows the results of (a) and FIG. 12 shows the results of (b).
- SU11274 was shown to significantly inhibit HGF-induced susceptibility of PC-9 to gefitinib, similar to anti-human HGF neutralizing antibody and NK4.
- SU11274 was shown to significantly inhibit the decrease in sensitivity of H1975 to CL-387,785 induced by HGF, similar to the anti-human HGF neutralizing antibody and NK4. .
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
肺癌におけるEGFRチロシンキナーゼ阻害薬の耐性に関して、非特許文献1には、ゲフィチニブ耐性を獲得した肺癌細胞にMET遺伝子の増幅が見られ、MET阻害剤とゲフィチニブとの併用により、当該ゲフィチニブ耐性肺癌細胞の増殖が抑制されたことが記載されている。また、本発明者らは、線維芽細胞との相互作用によるスキルス胃癌細胞へのゲフィチニブ耐性誘導がNK4の遺伝子治療の併用により抑制されたことを報告している(非特許文献2参照)。
[1]分子標的薬の治療対象の癌であるが該分子標的薬が無効な癌または該分子標的薬に対する感受性が低下している癌の該分子標的薬に対する感受性を増強する医薬組成物であって、HGF-MET受容体系阻害物質を含有することを特徴とする医薬組成物。
[2]無効な癌または感受性が低下している癌が、MET受容体遺伝子の増幅を伴わないことを特徴とする前記[1]に記載の医薬組成物。
[3]分子標的薬がEGFRチロシンキナーゼ阻害薬である前記[1]または[2]に記載の医薬組成物。
[4]EGFR阻害薬が可逆的EGFRチロシンキナーゼ阻害薬である前記[3]に記載の医薬組成物。
[5]EGFR阻害薬が不可逆的EGFRチロシンキナーゼ阻害薬である前記[3]に記載の医薬組成物。
[6]HGF-MET受容体系阻害物質が、抗HGF中和抗体、NK4、MET受容体チロシンキナーゼ阻害剤、抗MET受容体抗体、MET受容体発現抑制物質、およびMET受容体細胞外領域のHGF結合部分を有するタンパク質からなる群より選択される1種以上である前記[1]~[5]のいずれかに記載の医薬組成物。
[7]分子標的薬の治療対象の癌が、肺癌、乳癌、大腸癌、前立腺癌、脳腫瘍、膵臓癌、胆のう癌、腎癌、慢性骨髄性白血病、消化管間質腫瘍、食道癌、頭頸部腫瘍、または胃癌である前記[1]~[6]のいずれかに記載の医薬組成物。
[8]分子標的薬の治療対象の癌であるが該分子標的薬が無効な癌または該分子標的薬に対する感受性が低下している癌の治療薬であって、該分子標的薬とHGF-MET受容体系阻害物質とを組み合わせてなることを特徴とする癌治療薬。
[9]無効な癌または感受性が低下している癌が、MET受容体遺伝子の増幅を伴わないことを特徴とする前記[8]に記載の癌治療薬。
[10]分子標的薬がEGFRチロシンキナーゼ阻害薬である前記[8]または[9]に記載の癌治療薬。
[11]EGFR阻害薬が可逆的EGFRチロシンキナーゼ阻害薬である前記[10]に記載の癌治療薬。
[12]EGFR阻害薬が不可逆的EGFRチロシンキナーゼ阻害薬である前記[10]に記載の癌治療薬。
[13]HGF-MET受容体系阻害物質が、抗HGF中和抗体、NK4、MET受容体チロシンキナーゼ阻害剤、抗MET受容体抗体、MET受容体発現抑制物質、およびMET受容体細胞外領域のHGF結合部分を有するタンパク質からなる群より選択される1種以上である前記[8]~[12]のいずれかに記載の癌治療薬。
[14]分子標的薬の治療対象の癌が、肺癌、乳癌、大腸癌、前立腺癌、脳腫瘍、膵臓癌、胆のう癌、腎癌、慢性骨髄性白血病、消化管間質腫瘍、食道癌、頭頸部腫瘍、または胃癌である前記[8]~[13]のいずれかに記載の癌治療薬。
(1)実験材料
EGFRのアミノ酸配列の746位(E)~750位(A)を欠失している変異型EGFRを発現し、ゲフィチニブ感受性のヒト非小細胞肺癌細胞株PC-9(以下「PC-9」と記す)およびHCC827(以下「HCC827」と記す)を使用した。なお、両細胞ともゲフィチニブに対する耐性(感受性低下)に関与するEGFRの新たな変異ならびにMET受容体の遺伝子増幅ともに認められない細胞である。PC-9は免疫生物研究所から、HCC827はATCCからそれぞれ購入した。PC-9およびHCC827の培養には、10%FBS、ペニシリン(100unit/mL)、ストレプトマイシン(100unit/mL)、グルタミン(2mmol/L)を含むRPMI1640培地を用いた。
ゲフィチニブはアストラゼネカから入手した。HGF(組換えヒトHGFタンパク質)は、「Kato S, Funakoshi H, Nakamura T, et al. Acta Neuropathol. 2003 Aug;106(2):112-20.」の記載に基づいて作製した。EGFおよびIGF-Iはインビトロジェンから購入した。TGF-αはBiosourceから購入した。抗ヒトHGF中和抗体(ヤギ)およびコントロールIgG(ヤギ)は、R&D Systemから購入した。
(a)HGFによるゲフィチニブ耐性(感受性低下)の誘導
PC-9またはHCC827を96ウェルプレートに2×103個/ウェルで播種し、24時間培養した。24時間後に、ゲフィチニブおよびHGFを種々の濃度の組み合わせで添加した。すなわち、0.01~1μM(最終濃度)となるように5段階の濃度に調製したゲフィチニブを各ウェルに添加した。ゲフィチニブを添加しないウェルも設けた。さらに2~50ng/mL(最終濃度)となるように5段階の濃度に調製したHGF溶液を添加した。HGFを添加しないウェルも設けた。72時間の培養後、50μLのMTT溶液(2mg/mL、シグマ製)を添加し、37℃で2時間インキュベートした。培地を除去し、各ウェルに100μLのDMSOを添加して濃青色の結晶を溶解した。マイクロプレートリーダーMTP-120(コロナ電気)を用いて、検出波長550nm、参照波長630nmで吸光度を測定した。増殖率は、無処置対照に対する相対値で示した。各実験はトリプリケートで行い、独立した実験を3回実施した。
HGF溶液またはHGFを含まない溶媒(対照)に抗ヒトHGF中和抗体またはコントロールIgGを添加し、37℃で1時間前処理を行った。上記(a)と同様に、96ウェルプレートに2×103個/ウェルでHCC827を播種し、24時間培養後、0.3μM(最終濃度)のゲフィチニブを添加した。さらに、ゲフィチニブを添加したウェルまたはゲフィチニブを添加していないウェルに対して、上記前処理済の各溶液を添加し、72時間培養を続けた。培地中の最終濃度は、HGFが20ng/mL、抗ヒトHGF中和抗体が2μg/mL、コントロールIgGが2μg/mLであった。72時間の培養後、(a)と同様に、MTT法を用いて細胞の増殖を測定し、増殖率を算出した。
上記(a)と同様に、96ウェルプレートに2×103個/ウェルでPC-9またはHCC827を播種し、24時間後に、0.3μM(最終濃度)または1μM(最終濃度)となるようにゲフィチニブを添加した。さらに20ng/mL(最終濃度)となるようにHGF、EGF、TGF-αまたはIGF-Iを添加して72時間培養を続けた。ゲフィチニブを添加しないウェル、成長因子に変えて培地のみを添加したウェルをそれぞれ設けた。72時間の培養後、(a)と同様に、MTT法を用いて細胞の増殖を測定し、増殖率を算出した。
(a)の結果を図1(a)および図1(b)に、(b)の結果を図2に、(c)の結果を図3(a)および図3(b)にそれぞれ示した。
図1(a)および図1(b)から明らかなように、HGFは、PC-9およびHCC827のゲフィチニブに対する耐性を濃度依存的に誘導することが示された。また、図2から明らかように、抗HGF中和抗体で前処理したHGFはHCC827のゲフィチニブ耐性誘導能を喪失したが、コントロールIgGで前処理したHGFはHCC827のゲフィチニブ耐性誘導能を維持することがわかった。さらに、図3(a)および図3(b)から明らかなように、HGF以外の成長因子(EGF、TGF-α、IGF-I)は誘導するゲフィチニブ耐性はごくわずかであり、HGFのゲフィチニブ耐性誘導能が顕著であることが示された。
これらの結果は、たとえ、本来ゲフィチニブに感受性があり、なおかつゲフィチニブに対する耐性に関与するEGFRの新たな変異やMET受容体の遺伝子増幅のないヒト非小細胞肺癌細胞であっても、HGFはゲフィチニブに対する感受性を低下させること、すなわちゲフィチニブに対する耐性を促すことを示している。
(1)実験材料
細胞には、実施例1と同じPC-9を用いた。ゲフィチニブ、抗ヒトHGF中和抗体およびコントロールIgGは実施例1と同じものを使用した。
HGF発現ベクターは「Ueki T, Kaneda Y, Tsutsui H, et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nature Medicine 5, 226 - 230 (01 Feb 1999)」に従って作製した。トランスフェクション前日に、抗生物質を含まない培地を用いて調製したPC-9を2×104個/400μLで24ウェルプレートに播き、24時間培養した。この細胞にリポフェクタミン2000(1μL)を用いてHGF発現ベクターをトランスフェクションした(PC-9/HGF)。対照として、HGF遺伝子が挿入されていないベクターのみを同様にトランスフェクションした(PC-9/mock)。24時間培養後、PBSで細胞を洗浄し、0.3μM(最終濃度)のゲフィチニブ、2μg/mL(最終濃度)の抗ヒトHGF中和抗体、2μg/mL(最終濃度)のコントロールIgGを、それぞれ添加してまたは添加しないで72時間培養を続けた。72時間培養後、実施例1と同様にMTT法を用いて細胞の増殖を測定し、増殖率を算出した。
これらの結果から、HGFの遺伝子発現によってHGFを産生するようになるとゲフィチニブに対する耐性(すなわち感受性の低下)を獲得すること、さらに、そのゲフィチニブに対する耐性はHGFの活性中和、すなわちHGF-MET受容体系の阻害によって抑制されること、言換えればHGF-MET受容体系の阻害はHGFによってもたらされるゲフィチニブに対する耐性を抑制することが明らかとなった。
(1)実験材料
細胞には、実施例1と同じPC-9およびヒト胎児肺由来正常線維芽細胞MRC-5(以下「MRC-5」と記す)を使用した。MRC-5は、例えばATCCから入手可能である(ATCC No.CCL-171)。PC-9の培養には、10%FBS、ペニシリン(100unit/mL)、ストレプトマイシン(100unit/mL)、グルタミン(2mmol/L)を含むRPMI1640培地を用い、MRC-5の培養には、10%FBS、ペニシリン(100unit/mL)、ストレプトマイシン(100unit/mL)、グルタミン(2mmol/L)を含むDMEM培地を用いた。
ゲフィチニブはアストラゼネカから入手した。HGF(組換えヒトHGFタンパク質)およびNK4(組換えヒトNK4タンパク質)はクリングルファーマ株式会社から入手した。培養細胞実験用の抗ヒトHGF中和抗体(ヤギ)およびコントロールIgG(ヤギ)はR&D Systemから購入した。動物実験用の抗ヒトHGF中和抗体(イムノグロブリン)は、ウサギにヒトHGFタンパク質を投与することによって抗血清を調製し、抗血清からプロテインAカラムを用いたクロマトグラフィーによって精製した。ゲフィチニブは、濃度が2.5mg/mLとなるように1%Tween80含有水に懸濁し、投与用懸濁液とした。NK4および抗ヒトHGF中和抗体は生理食塩水(大塚製薬)を用いてそれぞれ1.13mg/mLおよび1.0mg/mLの濃度に調製にし、投与用溶液とした。
(a)MRC-5由来のHGFによるPC-9のゲフィチニブ耐性誘導および抗HGF中和抗体の効果
MRC-5(線維芽細胞)とPC-9(肺癌細胞)とを共培養する場合、トランスウェルチャンバー(24ウェル用、Coster社)を用いた。PC-9を8×103細胞/700μLにて下側のウェルに播種する一方、MRC-5を1×104細胞/300μLにて上側のウェルに播種し、24時間培養した。24時間培養後、0.3μM(最終濃度)のゲフィチニブを添加して、または添加しないで、さらに、2μg/mL(最終濃度)のコントロールIgGもしくは2μg/mL(最終濃度)の抗ヒトHGF中和抗体を添加して、または添加しないで、72時間培養を続けた。72時間培養後、実施例1と同様にMTT法を用いて下側のウェルに培養したPC-9の増殖を測定し、増殖率を算出した。
一方、PC-9を単独で培養する場合、PC-9を8×103細胞/700μLにて24ウェルプレートの各ウェルに播種し、24時間培養した。24時間培養後、50ng/mL(最終濃度)のHGFを添加して、または添加しないで、0.3μM(最終濃度)のゲフィチニブを添加して、または添加しないで、さらに、2μg/mL(最終濃度)のコントロールIgGもしくは2μg/mL(最終濃度)の抗ヒトHGF中和抗体を添加して、または添加しないで、72時間培養を続けた。72時間培養後、実施例1と同様にMTT法を用いて細胞の増殖を測定し、増殖率を算出した。
SCIDマウス(雌、5週齢)は日本クレアから購入した。
PC-9(5×106個)とMRC-5(5×106個)とを含む細胞浮遊液100μLをSCIDマウスの背部皮下に接種した。4日後、腫瘍の直径が4mmを超えたマウスを無作為に5匹ずつ群分けし、表1に示す6群を設けた。
2日ごとに腫瘍の幅および長さを測定し、腫瘍面積(幅×長さ)を算出した。本実験は腫瘍実験における動物の福祉に関する英国癌研究調整委員会の指針に従って実施した。
(a)の結果を図5に示した。図5中MediumはHGFを添加していない培地で培養したPC-9の増殖を、rhHGFはHGF(組換えヒトHGF)を添加した培地で培養したPC-9の増殖を、MRC-5はHGFを添加していない培地でMRC-5と共培養したPC-9の増殖をそれぞれ示す。図5からわかるように、PC-9をMRC-5と共培養することによっても、MRC-5が産生するHGFによって、培地にrhHGFを添加したときと同様にPC-9にゲフィチニブに対する耐性(感受性低下)が誘導され、そのゲフィチニブに対する耐性は抗ヒトHGF抗体によって抑制されることが明らかとなった。
上記実施例3と同様に、PC-9(5×106個)とMRC-5(5×106個)とを含む細胞浮遊液100μLをSCIDマウスの背部皮下に接種し、4日後に腫瘍を採取した。対照として、PC-9のみを同様に接種し、4日後に腫瘍組織を採取した。腫瘍組織をタンパク質分解酵素阻害剤カクテル(20 mM Tris-HCl (pH 7.5), 2 M NaCl, 0.1% Tween-80, 2 mM EDTA, 1 mM PMSF)中にてホモジナイズした後、12,000×gにて30分間遠心した。上清を抽出液とし、抽出液中のヒトHGFをELISAキット(IMMUNIS HGF EIA, Institute of Immunology)を用いて定量した。
(1)実験材料
ゲフィチニブ耐性かつCL-387,785感受性のヒト非小細胞肺癌細胞株H1975(以下「H1975」と記す)を使用した。H1975は、例えばATCCから入手可能である(ATCC No.CRL-5908)。H1975の培養には、10%FBS、ペニシリン(100unit/mL)、ストレプトマイシン(100unit/mL)、グルタミン(2mmol/L)を含むRPMI1640培地を用いた。
ゲフィチニブはアストラゼネカから入手した。CL-387,785はコスモバイオから入手した。HGF(組換えヒトHGFタンパク質)およびNK4(組換えヒトNK4タンパク質)はクリングルファーマ株式会社から入手した。抗ヒトHGF中和抗体(Lot No.ALP01)はR&D Systemsから購入した。
(a)H1975に対するゲフィチニブまたはCL-387,785の効果
80%コンフルエントのH1975を剥がして回収し、96ウェルプレートに2×103個/ウェルで播種し、24時間培養した。24時間後に、0.01~10μM(最終濃度)となるように7段階の濃度に調製したゲフィチニブまたはCL-387,785を各ウェルに添加し、72時間培養を続けた。50μLのMTT溶液(2mg/mL、シグマ製)を添加し、37℃で2時間インキュベートした。培地を除去し、各ウェルに100μLのDMSOを添加して濃青色の結晶を溶解した。マイクロプレートリーダーMTP-120(コロナ電気)を用いて、検出波長550nm、参照波長630nmで吸光度を測定した。増殖率は、無処置対照に対する相対値で示した。各実験はトリプリケートで行い、独立した実験を3回実施した。
上記(a)と同様に、96ウェルプレートに2×103個/ウェルでH1975を播種し、24時間培養後、0.03~3μM(最終濃度)となるように5段階の濃度に調製したCL-387,785を添加した。さらに50ng/mL(最終濃度)に調製したHGF溶液を添加してまたは添加しないで72時間培養を続けた。(a)と同様に、MTT法を用いて細胞の増殖を測定し、増殖率を算出した。
上記(a)と同様に、96ウェルプレートに2×103個/ウェルでH1975を播種し、24時間培養後、表2に示すように0.3μM(最終濃度)のCL-387,785、50ng/mL(最終濃度)のHGF、2μg/mL(最終濃度)の抗ヒトHGF中和抗体、0.3μM(最終濃度)のNK4をそれぞれ添加し、72時間培養を続けた。(a)と同様に、MTT法を用いて細胞の増殖を測定し、増殖率を算出した。
(a)の結果を図8に、(b)の結果を図9に、(c)の結果を図10にそれぞれ示した。図8に示したように、H1975はゲフィチニブに耐性、CL-387,785には感受性であった。図9から、HGFを培地に添加することにより、H1975のCL-387,785に対する感受性が低下することが明らかとなった。そして、図10から明らかなように、抗ヒトHGF中和抗体またはNK4は、HGFによって誘導されるH1975のCL-387,785対する感受性低下を阻害することが示された。すなわち、たとえHGFの作用によってH1975細胞のCL-387,785に対する感受性が低下したとしても、抗ヒトHGF中和抗体またはNK4はその感受性の低下を克服することが示された。
(1)実験材料
細胞には、PC-9またはH1975を使用した。PC-9およびH1975の培養には、10%FBS、ペニシリン(100unit/mL)、ストレプトマイシン(100unit/mL)、グルタミン(2mmol/L)を含むRPMI1640培地を用いた。
ゲフィチニブはアストラゼネカから入手した。CL-387,785はコスモバイオから入手した。HGF(組換えヒトHGFタンパク質)およびNK4(組換えヒトNK4タンパク質)はクリングルファーマ株式会社から入手した。抗ヒトHGF中和抗体(ヤギ)はR&D Systemから購入した。SU11274はカルバイオケムから入手した。
(a)HGFによるゲフィチニブ耐性PC-9に対するSU11274の効果
96ウェルプレートに2×103個/ウェルでPC-9を播種し、24時間培養後、表3に示すように20ng/mL(最終濃度)のHGF、0.3μM(最終濃度)のゲフィチニブ、1μg/mL(最終濃度)の抗ヒトHGF中和抗体、0.3μM(最終濃度)のNK4、0.3μM(最終濃度)のSU11274をそれぞれ添加し、72時間培養を続けた。50μLのMTT溶液(2mg/mL、シグマ製)を添加し、37℃で2時間インキュベートした。培地を除去し、各ウェルに100μLのDMSOを添加して濃青色の結晶を溶解した。マイクロプレートリーダーMTP-120(コロナ電気)を用いて、検出波長550nm、参照波長630nmで吸光度を測定した。増殖率は、無処置対照に対する相対値で示した。各実験はトリプリケートで行い、独立した実験を3回実施した。
96ウェルプレートに2×103個/ウェルでH1975を播種し、24時間培養後、表4に示すように0.3μM(最終濃度)のCL-387,785、50ng/mL(最終濃度)のHGF、2μg/mL(最終濃度)の抗ヒトHGF中和抗体、0.3μM(最終濃度)のNK4、1μM(最終濃度)のSU11274をそれぞれ添加し、72時間培養を続けた。(a)と同様に、MTT法を用いて細胞の増殖を測定し、増殖率を算出した。
(a)の結果を図11に、(b)の結果を図12にそれぞれ示した。図11から明らかなように、SU11274は、抗ヒトHGF中和抗体およびNK4と同様に、HGFによって誘導されるPC-9のゲフィチニブに対する感受性低下を有意に阻害することが示された。また、図12から明らかなように、SU11274は、抗ヒトHGF中和抗体およびNK4と同様に、HGFによって誘導されるH1975のCL-387,785に対する感受性低下を有意に阻害することが示された。
Claims (14)
- 分子標的薬の治療対象の癌であるが該分子標的薬が無効な癌または該分子標的薬に対する感受性が低下している癌の該分子標的薬に対する感受性を増強する医薬組成物であって、HGF-MET受容体系阻害物質を含有することを特徴とする医薬組成物。
- 無効な癌または感受性が低下している癌が、MET受容体遺伝子の増幅を伴わないことを特徴とする請求項1に記載の医薬組成物。
- 分子標的薬がEGFRチロシンキナーゼ阻害薬である請求項1または2に記載の医薬組成物。
- EGFR阻害薬が可逆的EGFRチロシンキナーゼ阻害薬である請求項3に記載の医薬組成物。
- EGFR阻害薬が不可逆的EGFRチロシンキナーゼ阻害薬である請求項3に記載の医薬組成物。
- HGF-MET受容体系阻害物質が、抗HGF中和抗体、NK4、MET受容体チロシンキナーゼ阻害剤、抗MET受容体抗体、MET受容体発現抑制物質、およびMET受容体細胞外領域のHGF結合部分を有するタンパク質からなる群より選択される1種以上である請求項1~5のいずれかに記載の医薬組成物。
- 分子標的薬の治療対象の癌が、肺癌、乳癌、大腸癌、前立腺癌、脳腫瘍、膵臓癌、胆のう癌、腎癌、慢性骨髄性白血病、消化管間質腫瘍、食道癌、頭頸部腫瘍、または胃癌である請求項1~6のいずれかに記載の医薬組成物。
- 分子標的薬の治療対象の癌であるが該分子標的薬が無効な癌または該分子標的薬に対する感受性が低下している癌の治療薬であって、該分子標的薬とHGF-MET受容体系阻害物質とを組み合わせてなることを特徴とする癌治療薬。
- 無効な癌または感受性が低下している癌が、MET受容体遺伝子の増幅を伴わないことを特徴とする請求項8に記載の癌治療薬。
- 分子標的薬がEGFRチロシンキナーゼ阻害薬である請求項8または9に記載の癌治療薬。
- EGFR阻害薬が可逆的EGFRチロシンキナーゼ阻害薬である請求項10に記載の癌治療薬。
- EGFR阻害薬が不可逆的EGFRチロシンキナーゼ阻害薬である請求項10に記載の癌治療薬。
- HGF-MET受容体系阻害物質が、抗HGF中和抗体、NK4、MET受容体チロシンキナーゼ阻害剤、抗MET受容体抗体、MET受容体発現抑制物質、およびMET受容体細胞外領域のHGF結合部分を有するタンパク質からなる群より選択される1種以上である請求項8~12のいずれかに記載の癌治療薬。
- 分子標的薬の治療対象の癌が、肺癌、乳癌、大腸癌、前立腺癌、脳腫瘍、膵臓癌、胆のう癌、腎癌、慢性骨髄性白血病、消化管間質腫瘍、食道癌、頭頸部腫瘍、または胃癌である請求項8~13のいずれかに記載の癌治療薬。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2756851A CA2756851A1 (en) | 2009-03-27 | 2009-10-09 | Therapeutic agent for cancer having reduced sensitivity to molecular target drug and pharmaceutical composition for enhancing sensitivity to molecular target drug |
US13/258,718 US20120064090A1 (en) | 2009-03-27 | 2009-10-09 | Therapeutic agent for cancer having reduced sensitivity to molecular target drug and pharmaceutical composition for enhancing sensitivity to molecular target drug |
JP2011505802A JP5579699B2 (ja) | 2009-03-27 | 2009-10-09 | 分子標的薬に対する感受性が低下している癌の治療薬および分子標的薬に対する感受性を増強する医薬組成物 |
US14/057,398 US20140056910A1 (en) | 2009-03-27 | 2013-10-18 | Therapeutic agent for cancer having reduced sensitivity to molecular target drug and pharmaceutical composition for enhancing sensitivity to molecular target drug |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009078621 | 2009-03-27 | ||
JP2009-078621 | 2009-03-27 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/258,718 A-371-Of-International US20120064090A1 (en) | 2009-03-27 | 2009-10-09 | Therapeutic agent for cancer having reduced sensitivity to molecular target drug and pharmaceutical composition for enhancing sensitivity to molecular target drug |
US14/057,398 Division US20140056910A1 (en) | 2009-03-27 | 2013-10-18 | Therapeutic agent for cancer having reduced sensitivity to molecular target drug and pharmaceutical composition for enhancing sensitivity to molecular target drug |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2010109706A1 true WO2010109706A1 (ja) | 2010-09-30 |
Family
ID=42780409
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2009/067630 WO2010109706A1 (ja) | 2009-03-27 | 2009-10-09 | 分子標的薬に対する感受性が低下している癌の治療薬および分子標的薬に対する感受性を増強する医薬組成物 |
Country Status (4)
Country | Link |
---|---|
US (2) | US20120064090A1 (ja) |
JP (1) | JP5579699B2 (ja) |
CA (1) | CA2756851A1 (ja) |
WO (1) | WO2010109706A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104245701A (zh) | 2012-04-03 | 2014-12-24 | 诺华有限公司 | 有酪氨酸激酶抑制剂的组合产品和其应用 |
US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
WO2014147631A1 (en) | 2013-03-22 | 2014-09-25 | Natco Pharma Limited | Formulation comprising gefitinib as oral suspension |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
JP2003250549A (ja) * | 2002-02-25 | 2003-09-09 | Kringle Pharma Inc | Nk4遺伝子または組換えnk4蛋白質からなる医薬 |
PE20091827A1 (es) * | 2008-04-11 | 2009-11-20 | Galaxy Biotech Llc | Combinacion del inhibidor hgf y el inhibidor egf para el tratamiento del cancer |
WO2010119991A2 (en) * | 2009-04-17 | 2010-10-21 | Takeda Pharmaceutical Company Limited | Novel method of treating cancer |
-
2009
- 2009-10-09 US US13/258,718 patent/US20120064090A1/en not_active Abandoned
- 2009-10-09 WO PCT/JP2009/067630 patent/WO2010109706A1/ja active Application Filing
- 2009-10-09 JP JP2011505802A patent/JP5579699B2/ja not_active Expired - Fee Related
- 2009-10-09 CA CA2756851A patent/CA2756851A1/en not_active Abandoned
-
2013
- 2013-10-18 US US14/057,398 patent/US20140056910A1/en not_active Abandoned
Non-Patent Citations (3)
Title |
---|
JEFFREY A. ENGELMAN, SCIENCE, vol. 316, 2007, pages 1039 - 1043 * |
P.A.ZUCALI, ANNALS OF ONCOLOGY, vol. 19, 2008, pages 1605 - 1612 * |
YOSHIHISA NAMIKI, INTERNATIONAL JOURNAL OF CANCER, vol. 118, 2006, pages 1545 - 1555 * |
Also Published As
Publication number | Publication date |
---|---|
JP5579699B2 (ja) | 2014-08-27 |
CA2756851A1 (en) | 2010-09-30 |
JPWO2010109706A1 (ja) | 2012-09-27 |
US20140056910A1 (en) | 2014-02-27 |
US20120064090A1 (en) | 2012-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lindsey et al. | Epidermal growth factor signaling in transformed cells | |
CN102596998B (zh) | 血管增殖病症的治疗 | |
US20120130144A1 (en) | Treatment of lung cancer with a nitrobenzamide compound in combination with a growth factor inhibitor | |
Du et al. | Decorin inhibits angiogenic potential of choroid-retinal endothelial cells by downregulating hypoxia-induced Met, Rac1, HIF-1α and VEGF expression in cocultured retinal pigment epithelial cells | |
TW200831538A (en) | VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors | |
US10011659B2 (en) | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI) | |
KR20110004462A (ko) | Cmet 및 axl 억제제, 및 erbb 억제제를 사용하여 암을 치료하는 방법 | |
Ahsan et al. | Efficacy of an EGFR-specific peptide against EGFR-dependent cancer cell lines and tumor xenografts | |
JP2019048822A (ja) | Egfr依存性疾患またはegfrファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における2−カルボキサミドシクロアミノウレア誘導体の使用 | |
TW200948380A (en) | Combination of HGF inhibitor and PTEN agonist to treat cancer | |
JP5579699B2 (ja) | 分子標的薬に対する感受性が低下している癌の治療薬および分子標的薬に対する感受性を増強する医薬組成物 | |
WO2012156975A9 (en) | COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER | |
JP2022027658A (ja) | チロシンキナーゼ阻害剤と併用してegf/egfr経路を抑制する方法および組成物 | |
CN116437957A (zh) | 用于治疗肺癌的抗PD-L1抗体和c-Met激酶抑制剂的联用药物组合物 | |
CN114712512B (zh) | 一种用于治疗her2阳性癌症的新型联合疗法 | |
Dai et al. | p53 plays a key role in the apoptosis of human ovarian cancer cells induced by adenovirus-mediated CRM197 | |
EP3176183A1 (en) | Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki) | |
KR20210053242A (ko) | 항암제 내성을 완화하고 항암제의 민감성을 강화하기 위한 약학적 조성물 및 그 용도 | |
JP5671487B2 (ja) | 放射線治療の有効性を増強するためのmet阻害剤 | |
CN112915202A (zh) | 喹啉衍生物与pd-1单抗的药物组合 | |
US20150037336A1 (en) | Combination of hb-egf binding protein and egfr inhibitor | |
WO2020081528A1 (en) | Method and system for treating cancer utilizing tinagl 1 | |
WO2024043252A1 (ja) | 癌の治療及び/又は予防のための医薬品 | |
CN111514298B (zh) | 质子泵抑制剂与pd-1轴结合拮抗剂的组合及其用途 | |
TWI842966B (zh) | 一種具緩解抗癌藥物抗藥性及增加抗癌藥物敏感性之醫藥組合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09842316 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2011505802 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2756851 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13258718 Country of ref document: US |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09842316 Country of ref document: EP Kind code of ref document: A1 |